Painceptor Pharma gains patent for lead drug

04-10-2006: PainCeptor Pharma Corp., a biopharmaceutical company focused on the development of novel therapeutics for the treatment of chronic and acute pain, announced that it has been awarded a series of milestone patents for its two lead drug development programs, NGF (nerve growth factor) and ASIC (acid sensing ion channel) antagonists.

The four patents granted PainCeptor are:

1. 'Neurotrophin Antagonists for the Treatment of Epilepsy, Alzheimer's Disease and Pain'' - patent allowed in Europe (#0930883) and Israel (#129475)

2. 'Method of Inhibiting Neurotrophin-Receptor Binding'' - patent issued in Australia (#781888)

3. "DNA Encoding a Human Proton-Gated Ion Channel and Uses Thereof'' - patent allowed in Europe (#EP-B-1025226)

4. "Method of Inhibiting Neurotrophin-Receptor Binding'' - US Divisional Patent allowed

These patents bring the total of PainCeptor's intellectual property portfolio to 39 issued patents; with an additional 45 patent applications under examination; and a further 10 provisional applications pending.